Premium
DPP‐4 inhibitors and risk of infections: a meta‐analysis of randomized controlled trials
Author(s) -
Yang Wenjia,
Cai Xiaoling,
Han Xueyao,
Ji Lig
Publication year - 2016
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/dmrr.2723
Subject(s) - vildagliptin , sitagliptin , alogliptin , saxagliptin , medicine , linagliptin , metformin , odds ratio , placebo , randomized controlled trial , type 2 diabetes , confidence interval , dipeptidyl peptidase 4 , relative risk , diabetes mellitus , sitagliptin phosphate , pharmacology , endocrinology , alternative medicine , pathology , insulin
Abstract Background To evaluate the risk of infections in the treatment of type 2 diabetes patients with dipeptidyl‐peptidase 4 (DPP‐4) inhibitors. Methods A literature search was conducted through electronic databases. The inclusion criteria included study duration of no less than 12 weeks developed in type 2 diabetes patients, the use of a randomized control group receiving a DPP‐4 inhibitor and the availability of outcome data for infections. Out of 2181 studies, 74 studies were finally included. Results The risk of overall infection for DPP‐4 inhibitors treatment was comparable to placebo (odds ratio (OR) = 0.97, 95% confidence interval (CI), 0.91 to 1.04, p = 0.40), metformin treatment (OR = 1.22, 95% CI, 0.95 to 1.56, p = 0.12), sulphonylurea treatment (OR = 1.09, 0.93 to 1.29, p = 0.29), thiazolidinedione treatment (OR = 0.86, 95% CI, 0.65 to 1.14, p = 0.29) and alpha glucosidase inhibitor treatment (OR = 1.03, 95% CI, 0.33 to 3.22, p = 0.96). When compared different DPP‐4 inhibitors with placebo treatment, risks of infections were comparable for alogliptin, linagliptin, sitagliptin, saxagliptin and vildagliptin. Compared with placebo or active comparator treatment, risks of infection in different systems for DPP‐4 inhibitors were all comparable. Conclusions The overall risk of infections of DPP‐4 inhibitor was not increased compared with control groups. Copyright © 2015 John Wiley & Sons, Ltd.